Adial Shareholders Approve 5x Authorized Share Increase and New Equity Plans; Four Proposals Adjourned to Oct 1
ADIL has more than doubled off its 52-week low of $1.31.
Summary
Adial shareholders approved a 5x increase in authorized shares and new equity plans at the September 17 annual meeting, but the vote on four Azora merger-related proposals was adjourned to October 1 pending Nasdaq approval.
Key Events · Corporate Governance and Compliance · ADIL
-
Authorized Shares Increased 5x
Shareholders approved an amendment to the certificate of incorporation increasing authorized common stock from 100,000,000 to 500,000,000 shares, providing headroom for the Azora reverse merger and PIPE financing.
-
New Equity Plans Approved
The 2026 Equity Incentive Plan was approved with a share reserve of 3,078,147 shares plus 196,670 returning shares, and the 2026 Employee Stock Purchase Plan was approved with 307,815 shares. Amendment No. 8 to the 2017 Plan increased its reserve from 200,000 to 225,666 shares.
-
Four Proposals Adjourned to October 1
Votes on Proposals 3, 4, 5 and 6 — including Azora merger-related items — were adjourned to October 1, 2026 at 8:30 a.m. ET because Nasdaq has not yet granted conditional approval of the Initial Listing Application.
-
Nasdaq Listing Uncertainty Persists
The adjournment is tied to pending Nasdaq approval, extending the listing compliance uncertainty previously disclosed in the August 14 10-Q and August 21 8-K.
Analysis · ADIL · Life Sciences
The 2026 Annual Meeting on September 17, 2026 delivered several material outcomes for Adial. Shareholders approved an amendment that increases authorized shares from 100 million to 500 million—a fivefold expansion providing the headroom needed for the Azora reverse merger and PIPE financing already quantified in the August 24 proxy as up to 53.4 million new shares. The meeting also approved a new 2026 Equity Incentive Plan with a 3.08 million share reserve and a 2026 Employee Stock Purchase Plan with 307,815 shares. Critically, the vote on Proposals 3, 4, 5 and 6—which include the Azora merger-related items—was adjourned to October 1, 2026 because Nasdaq has not yet granted conditional approval of the Initial Listing Application. This delay extends the uncertainty around the reverse merger and the company's Nasdaq listing compliance, which was already flagged as deficient in the August 14 10-Q and August 21 8-K.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADIL was trading at $4.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.8M. The 52-week trading range was $1.31 to $10.75. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.